Tweet
Chicago Independent Press
<img alt="" height="1" width="1" />
Merck Halts Study of Once-Daily HIV Drug
Wall Street Journal
Merck & Co. said Monday it will end a study of HIV drug Isentress after initial results showed a once-daily dosage wasn't as effective as the standard twice-daily regimen. Merck had hoped a once-daily Isentress would be a more ...
Merck's HIV drug Isentress fails once-a-day studyReuters
Merck to stop late-stage study of HIV treatmentBusinessWeek
Isentress Testing Ends, Daily Dose Not EnoughChicago Independent Press
Forbes (blog) -Aidsmap -Genetic Engineering News
all 32 news articles »
More...